Table 4. Subgroup analysis for CR (complete remission).
| Subgroup Analysis for CR | ||||
|---|---|---|---|---|
| Outcome | Subgroup | Trials | RR M-H, Fixed, 95%CI, P value | Heterogeneity I², P value |
| CR according to age in Group 1 | <65 years old | 3 | 1.24[1.15,1.34]p<0.00001 | 55%,p = 0.11 |
| >65 years old | 1 | 1.08[0.93,1.25]p = 0.34 | not applicable | |
| CR according to cytogenetic risk in Group 1 | favorable risk | 2 | 1.14[1.01,1.29]p = 0.03 | 0%,p = 0.39 |
| intermediate risk | 2 | 1.11[1.00,1.23]p = 0.04 | 0%,p = 0.87 | |
| unfavorable risk | 2 | 1.35[1.04,1.75]p = 0.02 | 0%,p = 0.60 | |
| CR according to cytogenetic risk in Group 2 | favorable risk | 3 | 1.06[0.99,1.13]p = 0.09 | 0%,p = 0.88 |
| intermediate risk | 3 | 0.94[0.88,1.01]p = 0.11 | 0%,p = 0.72 | |
| unfavorable risk | 3 | 0.80[0.59,1.08]p = 0.14 | 0%,p = 0.81 | |
Group 1, high doses of daunorubicin vs. low doses of daunorubicin
Group 2, high doses of daunorubicin vs. Idarubicin
RR, risk ratio; M–H, Mantel–Haenszel method; Fixed, fixed-effect model; CI, confidence interval.